February 2012

Premium Messaging (A2P SMS and P2A SMS) Market Volume Is Expected To Reach 1,134.2 Billion Globally By 2017: Transparency Market Research

According to a new report published by Transparency Market Research “Premium Messaging Market – A2P SMS Market, P2A SMS Market: Global Analysis, Trends, Size and Forecast (2007 – 2017)”. The global premium messaging market volume was165.9 billion in 2011 and is estimated to be 236.9 billion in 2012 and further expected to reach to 1,134.2 billion in 2017 at an estimated CAGR of 36.8% from 2012 to 2017. Browse the full

Tablet Sales to End Users Is Expected To Reach 248.6 Million Units by 2015, Smartphone’s Sales to End Users Will Reach 1,048.0 Million Units by 2015: Transparency Market Research

According to a new market report published by Transparency Market Research “Tablet Market and Smartphones Market: Global Database & Forecast (2010 – 2015)”, Global Tablet sales to end users reached 67.0 million units in 2011 and is expected to reach 248.6 million units by the end of 2015, growing at a CAGR of 38.8% from 2011 to 2015. Asia – Pacific (including Japan) is expected to enjoy the highest share

Feed Additives Market and Compound Feed Market - Global Market Size, Share, Segment And Geographic Analysis

The compound feed industry plays a major part in food chain which provides sustainable and nutritious food. The major forces driving the compound feed market are increase in the use of animal derived products in direct human consumption due to growing population and rising disposable income in developing countries. Browse full report at: http://www.transparencymarketresearch.com/compound-feed-and-additives-market.html The rise in demand of healthy and safe animal derived food as a result of increased

Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)

In 2009, the global Osteoporosis drug market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted largest share in class, respectively, and showed an average sales growth rate of about of 20% in the past 2 years. Browse Full Report at: http://www.transparencymarketresearch.com/osteoporosis-drug-market.html Amgen’s Denosumab is the recent entrant to the Osteoporosis treatment market, following